GSK1360707F

The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources:  –  ·  ·  · scholar · JSTOR (August 2014) (Learn how and when to remove this template message)

GSK1360707F

Identifiers
show IUPAC name (1R,6S)-1-(3,4-Dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane
CAS Number	1013098-04-8 Y
PubChem CID	24802841
ChemSpider	32739425
UNII	9DE44WJ46X
Chemical and physical data
Formula	C14H17Cl2NO
Molar mass	286.20 g·mol−1
3D model (JSmol)	Interactive image
show SMILES COC[C@@]12C[C@@]1(CCNC2)c3ccc(c(c3)Cl)Cl
show InChI InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1 Key:ICXJGCSEMJXNQF-KBPBESRZSA-N

GSK1360707F is a potent and selective triple reuptake inhibitor.^[1] It is chemically related to amitifadine and NS-2359 (GSK-372,475). Until recently,^[when?] it was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.^{[citation needed]}

Synthesis[]

Synthesis of GSK1360707F^[2]

1. BOC Protecting group.
2. Enolization and trapping with triflate group (cf Comins' reagent).
3. Suzuki reaction
4. Reduction (only 1 mol eq. LAH because N-BOC can be reduced to N-Me)
5. Trifluoroacetic acid (TFA) removal of protecting group.
6. Simmons–Smith reaction cyclopropanation.
7. Williamson ether synthesis (c.f. NS patents & paxil).

Transporter occupancy[]

GSK1360707F has recently (2013) been tested on baboons (Papio anubis) & humans for transporter occupancy using PET.^[3]

See also[]

• NS-2359

References[]